FDA Approves Kresladi Gene Therapy for Immune Disorder

The U.S. Food and Drug Administration (FDA) has approved Kresladi, a groundbreaking one-time gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic immune disorder. This recent approval marks a significant milestone in the treatment of a condition affecting approximately one in one million children globally. LAD-I is characterized by recurrent infections and can lead to early mortality due to the inability of white blood cells to respond effectively to infections. The therapy offers new hope for affected children and their families by correcting the underlying genetic defect.

Historically, severe leukocyte adhesion deficiency-I has posed considerable challenges. Mutations in the ITGB2 gene disrupt the normal function of proteins essential for immune response, leading to a compromised immune system that makes children vulnerable to life-threatening bacterial and fungal infections. Without treatment, the prognosis for these patients is dire, with survival beyond childhood being rare.

The development of Kresladi reflects over 30 years of research led by Dr. Donald Kohn, who has dedicated his career to advancing gene therapies for rare pediatric immune disorders. The clinical trial that led to the approval of Kresladi involved nine patients aged between 5 months and 9 years, treated at UCLA and other locations in London and Spain. The trial aimed to assess the safety and efficacy of the therapy, which works by adding a healthy copy of the ITGB2 gene to the patients' blood stem cells. These modified cells are then returned to the patient, enabling the production of functional immune cells.

Remarkably, all nine patients in the trial survived without requiring bone marrow transplants, and significant reductions in severe infections were observed. The success of this trial demonstrates the potential of gene therapy as a viable alternative to traditional treatments, such as bone marrow transplantation, which often involves extensive chemotherapy and immunosuppressive drugs. The approval of Kresladi is not only a victory for the patients who will benefit from this therapy but also a testament to the collaborative efforts of various research institutions and organizations, including Rocket Pharmaceuticals and the California Institute for Regenerative Medicine (CIRM).

CIRM, established in 2004 to accelerate stem cell therapies, co-funded clinical trials for Kresladi and celebrates this approval as a significant achievement in regenerative medicine. This milestone is expected to encourage further investment in the development of treatments for other rare diseases, paving the way for continued advancements in gene therapy. Looking ahead, the approval of Kresladi opens new doors for patients with severe leukocyte adhesion deficiency-I and other rare genetic disorders.

The therapy is anticipated to be available through specialized treatment centers experienced in ex vivo gene therapy procedures. Long-term follow-up data from treated patients will be crucial in confirming the clinical benefits of this innovative therapy. Dr. Kohn remains optimistic about the future, expressing hope that this approval will inspire other companies to invest in rare disease treatments and recognize the pathways available to make these therapies commercially viable. As research continues, there is potential for developing additional therapies for conditions like ADA-SCID, further enhancing the landscape of treatment options for rare immune disorders.